BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
T cell differentiation
,
Ischemia
,
Adipose tissue
,
Anticancer prodrugs
,
Aspirin
,
MDM2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
IL 23 p19
Summary
General Info
Curated Studies
Most Correlated Studies
CD4+ T cells differentiation into Th17 cells in the presence of TGF-beta1 and IL-6
CD4+ T cells activated and differentiated with Th17-inducing cytokine combinations
Colons of MDR1A KO mice with Helicobacter bilis colitis treated with interleukin blocking antibodies
Lungs exposed to alpha-hemolysin-positive and negative strains of Staphylococcus aureus
Explore Curated Studies Results
Literature
Most Relevant Literature
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasi…
Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and…
Riemerella anatipestifer infection in ducks induces IL-17A production, but not IL-23p19.
Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
Mirikizumab: First Approval.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic …
IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, …
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Sever…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ